Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Not to Expect Gov't to Adopt ATP Soon: Mr Butler of PhRMA -2-
October 22, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 22, 2001
- Mitsubishi Pharma Establishes Subsidiaries in US, UK
October 22, 2001
- Industry Expresses Opinions on Pricing of Medical Devices: Chuikyo
October 22, 2001
- Losses Reported by 19 of 93 FJPWA Member Wholesalers
October 22, 2001
- GE Marquette Medical Systems: Ultra-small ECG Recorder "SEER Light"
October 22, 2001
- BUSINESS NEWS IN BRIEF -1-
October 22, 2001
- Hac Kimisawa: Half-year Ordinary Profits Up 13.8%
October 22, 2001
- BUSINESS NEWS IN BRIEF -2-
October 22, 2001
- Sugi Yakkyoku: Sales, Profits Up Over 30% in First Half
October 22, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
October 22, 2001
- OTC NEW IN BRIEF
October 22, 2001
- Bungyo Rate Increases to 42.8% in June
October 15, 2001
- Cooperation for Immediate PMS Urged by SD Director
October 15, 2001
- WORLD NEWS IN BRIEF
October 15, 2001
- Korosho to Reduce Number of Hospital Beds by Shortening Hospital Stay
October 15, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 15, 2001
- REGULATORY NEWS IN BRIEF
October 15, 2001
- Etiology of Alzheimer Disease Should Be Clarified by 2013
October 15, 2001
- Mr Nagayama Calls For Drug Prices Proportional to Value
October 15, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…